Overview: "Stay current with this mid-year clinical update featuring the June 2025 FDA approval of lenacapavir for HIV pre-exposure prophylaxis (PrEP). This downloadable job aid provides a concise clinical snapshot of the medication: including key considerations for administration, safety, and patient adherence. Whether you have already completed the HIVPCP Certification Program or are just starting, this tool is designed to equip you with the essential information to incorporate this new PrEP option into informed clinical decision-making."
Module 1: HIV Prevention: Epidemiology, Interventions, and Public Health Strategies
Faculty: Maranda Ward, Ed.D., MPH
Maranda Ward, Ed.D., MPH has no relevant financial interests/relationships or affiliations to discloseCourse Description:
This course provides an overview on HIV in the U.S., touching on history, disparities, policies, and public health strategies, while emphasizing the importance of the HIV Prevention certification.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Describe the role of the HIV Prevention certification
- Review current epidemiology of HIV in the United States
- Describe disparities of HIV infection and access to prevention methods
- Identify public health strategies and clinical interventions for HIV prevention
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 2: HIV Testing, Assessing Exposure, and Maintaining Serostatus Negative
Faculty: Jonathan Appelbaum, MD, FACP, AAHIVS
Jonathan Appelbaum, MD, FACP, AAHIVS has a financial relationship/interest or affiliation in the form of:
Advisory board for EMD SeronoAll relevant financial relationships have been mitigated.
Course Description:
This course provides information on screening and diagnosing HIV, risk identification, short behavioral interventions, a status-neutral care approach for HIV services, and the importance of sexually transmitted infection screening and HIV treatment.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Explain the provision of HIV-related services through a status neutral care approach
- Explain how to identify vulnerability to HIV infection
- Identify appropriate short behavioral interventions
- Describe screening for and diagnosing HIV infection
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-040-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 3: Biomedical Strategies for Preventing HIV
Faculty: Brian Wood, MD
Brian Wood, MD has no relevant financial interests/relationships or affiliations to discloseCourse Description:
This course provides an outline for preventing HIV through PEP, PrEP, and TasP, covering clinical basics, research findings, CDC's guidance on PrEP, and emerging modalities.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Describe the clinical basics of prescribing PEP
- Describe the clinical basics of prescribing PrEP
- Discuss CDC’s guidance on oral and injectable PrEP
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-041-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 4: Enhancing Cultural Humility and Understanding Barriers to Care
Faculty: Aniruddha Hazra, MD
Aniruddha Hazra, MD has a financial relationship/interest or affiliation in the form of:
Advisory Board/Consultant for Gilead Sciences and Viiv Healthcare
Research Grant: Gilead Sciences
All relevant financial relationships have been mitigated.
Course Description:
This course provides a review of the HIV care continuum, impact of intersectional stigma on risk, cultural humility, trauma-informed care, and resources to mitigate financial barriers for clients.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Discuss the role of intersectional stigma, discrimination, trauma, and social determinants of health in HIV risk
- Explain cultural humility, the role it plays in providing HIV care, and overcoming barriers to care
- Describe trauma-informed care and its importance in HIV treatment and prevention
- Introduce resources to mitigate financial barriers for clients
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-042-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 5: PrEP Adherence & Persistence
Faculty: Roger Bedimo, MD, MS, FACP
Roger Bedimo, MD, MS, FACP has a financial relationship/interest or affiliation in the form of:
Advisory Board/Consultant: Merck, ViiV Healthcare, Theratechnologies and Gilead Sciences.
Research Grant: Merck
All relevant financial relationships have been mitigated.
Course Description:
This course provides insight on vulnerable populations with PrEP disparities, impact of SDOH and barriers to PrEP, navigation models for access, and provider strategies for supporting adherence.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Describe the facilitators and challenges that impact PrEP uptake and adherence
- Review strategies to support patient adherence and education
- Describe considerations for starting, switching, and stopping PrEP
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-043-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 6: Population-Based Considerations for PrEP
Faculty: Hyman Scott, MD, MPH
Hyman Scott, MD, MPH has no relevant financial interests/relationships or affiliations to discloseCourse Description:
This course provides information on population-based considerations for PrEP, including the role of PrEP and TASP with family planning, health models to improve PrEP access, and combination HIV and STI treatment and prevention strategies.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Identify populations vulnerable to HIV infection who also experience disparities around PrEP
- Review considerations for providing PrEP in populations with highest HIV incidence
- Describe service delivery models that improve access to PrEP
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-044-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Module 7: State of HIV Prevention and PrEP in 2025: Certification Maintenance for HIVPCPs
Faculty: Monica Gandhi, MD, MPH
Monica Gandhi, MD, MPH has no relevant financial interests/relationships or affiliations to discloseCourse Description:
This course provides an update on the current state of the HIV epidemic, key biomedical advances in HIV prevention, and evidence-based approaches to HIV prevention.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Describe current HIV epidemiologic data and PrEP use-to-need data
- Identify considerations for implementing long-acting HIV prevention in clinical settings
- Review forthcoming biomedical advances in HIV and STI prevention
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-045-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Pharmacy-Based HIV Prevention and PrEP
Faculty: Melissa Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP
Melissa Badowski, PharmD, MPH, FCCP, FIDSA, BCIDP, BCPS, AAHIVP has no relevant financial interests/relationships or affiliations to disclose
Course Description:
Pharmacists who complete all modules of the HealthHIV HIV Prevention Certified Provider Certification Program™, including the Pharmacy-Based HIV Prevention and PrEP module, may receive a Pharmacy-Based HIV Prevention Certified Provider certification.
Target Audience
This activity is intended for providers (physicians, PAs, NPs, nurses, pharmacists), allied health professionals (navigators, case managers, social workers, disease intervention specialists, health educators) and other healthcare professionals involved in the care of patients at risk for acquiring HIV.
- Media: Enduring Material
- Release date: April 2, 2025
- Expiration date: April 2, 2027
- Time to Complete: 60 minutes per module
Educational Objectives
After completing this activity, the participant will be better able to:
- Identify state guidance and regulations that allow pharmacists to prescribe PrEP
- Describe effective HIV testing in pharmacies
- Describe effective eligibility screening and PrEP counseling strategies in pharmacies
- Educate the patient on PrEP adherence, safety precautions, and the importance of regular monitoring for optimal HIV prevention
- Apply strategies for initiating PrEP in pharmacy settings through real-world case studies
Accreditation, Credit, and Support
Participants can earn up to 1.0 credits/contact hours (CME, MOC, ANCC, ACPE, AAPA, ASWB) for completion of this module.
In support of improving patient care, this activity has been planned and implemented by HealthHIV. HealthHIV is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
HealthHIV designates this continuing education activity for up to 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Type of Activity: Knowledge
Please see below for UAN number:
JA4008396-0000-26-046-H02-P
Support Statement
This program has been supported by an independent educational grant from Gilead Sciences, Inc and ViiV Healthcare.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from HealthHIV the accredited provider do not have any relevant financial relationships to disclose with ineligible companies.
Disclosure & Conflict of Interest Policy
HealthHIV is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, HealthHIV requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to HealthHIV policy. These disclosures will be provided to learners prior to the start of the CE activity.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. Your certificate will be available on eHealthHIV.org. If you have questions regarding your certificate, please contact Beth Brooks via email at beth@healthhiv.org.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit (75% is required for ABS).
For Pharmacists, HealthHIV will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
HealthHIV is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of HealthHIV.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of HealthHIV or any of its partners, providers, and/or supporters.
Final Certificate and Toolkit
After you have completed all seven HIVPCP modules, select this module to receive a final certificate and confirm your HIVPCP™ certification.
Once you obtain your certificate, you can register for the national database and access your toolkit materials including an e-mail signature, social media assets, office posters, and palm cards.